Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): 12 analysts have set the short term price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at $115.75. The standard deviation of short term price target has been estimated at $22.17, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 155 and $75 respectively.
Many analysts have stated their opinion on the company shares. Brokerage firm Goldman Sachs downgrades its rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). As per the latest information, the brokerage house lowers the price target to $88 per share from a prior target of $109. The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on April 28, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities,The director of Vertex Pharmaceuticals Inc / Ma, Boger Joshua S sold 5,130 shares at $95.25 on June 8, 2016. The Insider selling transaction had a total value worth of $488,633. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.95 points or 1.04% at $90.54 with 1,209,507 shares getting traded. Post opening the session at $91.24, the shares hit an intraday low of $90.06 and an intraday high of $92.47 and the price was in this range throughout the day. The company has a market cap of $22,395 million and the number of outstanding shares have been calculated to be 247,349,860 shares. The 52-week high of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is $143.45 and the 52-week low is $75.9.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.